 |
Vol.51 No.2 contents | Japanese/English |
 | Full Text of PDF (229K) Article in Japanese |
- The 24th Lung Cancer Workshop -
Outpatient Chemotherapy and Clinical Pathway for Advanced Non-small-cell Lung Cancer
Kiyoshi Komuta1, Takeshi Nakatani1, Kohei Okafuji1, Takayuki Shiroyama1, Seigo Minami1, Yoshitaka Ogata1, Chikako Kobayashi1, Suguru Yamamoto11Department of Respiratory Medicine, Osaka Police Hospital, Japan
We retrospectively investigated backgrounds, response rate and median overall survival 387 cases of non-small-cell lung cancer in which outpatient chemotherapy was performed between 1999 and 2008. The patients were 253 men and 134 women with a median age of 62 years (range, 32-83 years). Assessment of therapeutic effect revealed complete response and partial response in 145 of the 387 cases, and the efficacy rate was 37.5%. The disease control rate was 88.1%. The median overall survival time was 17.8 months, and the estimated median one-year survival rate was 62.2%. A clinical pathway using carboplatin+weekly paclitaxel, gemcitabine+vinorelbine, and docetaxel was devised for non-small-cell lung cancer. Introduction of a clinical pathway successfully reduced inpatient days, standardized treatment, and introduced outpatient chemotherapy.
key words: Clinical pathway, Outpatient chemotherapy, Non-small-cell carcinoma
JJLC 51 (2): 119-121, 2011
